UK markets closed

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
1.1400-0.0300 (-2.56%)
At close: 04:00PM EDT
1.1400 0.00 (0.00%)
After hours: 04:06PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
6,848
8,312
-14,927
-27,582
-6,523
Depreciation & amortisation
1,233
1,191
1,086
1,118
1,302
Deferred income taxes
-3,230
-3,092
0
0
-
Stock-based compensation
3,883
3,448
2,085
2,375
3,126
Change in working capital
-1,753
-10,539
-12,015
9,901
-27,130
Accounts receivable
-2,505
-428
-1,194
-1,032
2,091
Inventory
-2,043
-2,241
1,150
-4,872
-4,927
Other working capital
4,369
-2,467
-25,628
-11,744
-26,761
Other non-cash items
-1,060
-600
-689
3,090
3,641
Net cash provided by operating activities
5,868
-1,318
-25,000
-10,285
-26,106
Cash flows from investing activities
Investments in property, plant and equipment
-1,499
-1,149
-628
-1,459
-655
Purchases of investments
-
-20,420
-16,000
-37,835
-20,000
Sales/maturities of investments
-
5,000
11,000
57,835
0
Other investing activities
-130
-142
593
327
703
Net cash used for investing activities
-22,049
-16,711
-5,035
18,921
-19,952
Cash flows from financing activities
Debt repayment
-
0
0
-34,122
-215
Common stock issued
9,721
23,954
8,236
46,200
46,210
Net cash used provided by (used for) financing activities
10,433
24,666
8,238
12,078
46,467
Net change in cash
-5,827
6,523
-21,874
20,720
473
Cash at beginning of period
33,036
17,111
38,985
18,265
17,792
Cash at end of period
27,288
23,634
17,111
38,985
18,265
Free cash flow
Operating cash flow
5,868
-1,318
-25,000
-10,285
-26,106
Capital expenditure
-1,499
-1,149
-628
-1,459
-655
Free cash flow
4,369
-2,467
-25,628
-11,744
-26,761